I-M. M. Klymkovych
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
I-M. M. Klymkovych has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Andrii Ju Labyntsev
Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine
1 shared publication - Andrii Siromolot
Department of Technologies of Medical Diagnostics and Treatment, ESC “Institute of Biology and Medicine”, Taras Shevchenko National University of Kyiv, Volodymyrska Street 60, 01033 Kyiv, Ukraine
1 shared publication D. V. Kolybo
Department of Molecular Immunology, Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv
1 shared publication- Mariia Loboda
Department of General and Soil Microbiology, D.K. Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine, Akademika Zabolotnoho Str., 154, 03143 Kyiv, Ukraine
1 shared publication - O. S. Molozhavaya
Department of Microbiology and Immunology, ESC “Institute of Biology and Medicine”, Taras Shevchenko National University of Kyiv, Ukraine
1 shared publication - Svitlana Romaniuk
Department of Molecular Immunology O.V. Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine Kyiv Ukraine
1 shared publication
Latest Publications
- Open Access
- 16 June 2026
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in The Ukrainian Biochemical Journal
- Vol. 98 (3) , 101-111
Curcumin boosts doxorubicin cytotoxicity in breast cancer cells
Background. Breast cancer remains the leading cause of cancer mortality in women due to the resistance to chemotherapy and severe side effects of doxorubicin (Doxo). One of the approaches to overcome this problem is to search for phytocompounds that can enhance the efficacy of chemotherapy and prevent the development of side effects. Objective. This work aimed to investigate in vitro whether the polyphenol curcumin (Cur) from turmeric (Curcuma longa) in combination with the commercial drug Doxo-HCl can enhance the cytotoxic effect of Doxo on breast cancer cell lines MDA-MB-231 and MCF-7 and to exhibit chemoprotective activity against normal HEK-293 cells. Methods. Cell viability was assessed with MTT assay, apoptosis induction by flow cytometry with Annexin V–eGFP and PI, reactive oxygen species (ROS) generation by the DCFH-DA probe. The combination index (CI) calculation method and CompuSyn, Biosoft software were used to determine the synergism or antagonism of the components. Results. The study revealed dose-dependent cytotoxicity, increased ROS formation, and increased morphological aberrations in cells when using the combination of Cur with Doxo-HCl compared to Doxo-HCl. Cur acted as a chemosensitizer, which synergistically enhanced the antitumor activity of Doxo-HCl while simultaneously reducing its cytotoxic effects in normal cells by reducing ROS production. Conclusions. The use of Cur in combination with Doxo-HCl will likely reduce the effective therapeutic dose of Doxo and increase the effectiveness of breast cancer chemotherapy. Keywords: apoptosis, breast cancer cell lines, cell viability, chemosensitizer, combination index, combined treatment, curcumin, doxorubicin, oxidative stress
- 16 June 2026
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in The Ukrainian Biochemical Journal
- Vol. 98 (3) , 101-111
Open AccessCurcumin boosts doxorubicin cytotoxicity in breast cancer cells
Background. Breast cancer remains the leading cause of cancer mortality in women due to the resistance to chemotherapy and severe side effects of doxorubicin (Doxo). One of the approaches to overcome this problem is to search for phytocompounds that can enhance the efficacy of chemotherapy and prevent the development of side effects. Objective. This work aimed to investigate in vitro whether the polyphenol curcumin (Cur) from turmeric (Curcuma longa) in combination with the commercial drug Doxo-HCl can enhance the cytotoxic effect of Doxo on breast cancer cell lines MDA-MB-231 and MCF-7 and to exhibit chemoprotective activity against normal HEK-293 cells. Methods. Cell viability was assessed with MTT assay, apoptosis induction by flow cytometry with Annexin V–eGFP and PI, reactive oxygen species (ROS) generation by the DCFH-DA probe. The combination index (CI) calculation method and CompuSyn, Biosoft software were used to determine the synergism or antagonism of the components. Results. The study revealed dose-dependent cytotoxicity, increased ROS formation, and increased morphological aberrations in cells when using the combination of Cur with Doxo-HCl compared to Doxo-HCl. Cur acted as a chemosensitizer, which synergistically enhanced the antitumor activity of Doxo-HCl while simultaneously reducing its cytotoxic effects in normal cells by reducing ROS production. Conclusions. The use of Cur in combination with Doxo-HCl will likely reduce the effective therapeutic dose of Doxo and increase the effectiveness of breast cancer chemotherapy. Keywords: apoptosis, breast cancer cell lines, cell viability, chemosensitizer, combination index, combined treatment, curcumin, doxorubicin, oxidative stress